The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2024 | A project to improve the understanding of disease biology and treatment outcomes in myeloma
Elena Zamagni, MD, PhD, University of Bologna, Bologna, Italy, discusses a study to improve the understanding of disease biology and treatment outcomes for patients with multiple myeloma. The study includes two parts: the collection of real-world data and clinical information to better understand treatment outcomes, and the biobanking project, which aims to collect and store samples from 5,000 patients, with the goal of improving the understanding of the disease. This interview took place at the 66th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
We had the opportunity to share what we are doing in Italy with real-world data and registries. So mainly we have in Italy a myeloma registry which is actively enrolling up to 1,900 patients. So the goal of course is to collect all demographic clinical data to be able to have a real look on the outcome of patients, different treatments among the countries, what is related to quality of life and so on...
We had the opportunity to share what we are doing in Italy with real-world data and registries. So mainly we have in Italy a myeloma registry which is actively enrolling up to 1,900 patients. So the goal of course is to collect all demographic clinical data to be able to have a real look on the outcome of patients, different treatments among the countries, what is related to quality of life and so on. The second project that we discussed is the biobanking project that’s not only Italian, it’s Italy plus the Netherlands plus other European countries. We have the opportunity to have this study aimed at the biobanking 5,000 patients. So biobanking, what does it mean? Both bone marrow, peripheral blood and eventually extramedullary sites of the disease. So with the aim of putting those samples available for whatever project it will come, so maybe to look at MRD negativity in those patients in real life that don’t have a baseline sample, look at specific subset population, extramedullary disease, plasma cell leukemia and so on. So I think that’s a huge treasure, so it’s a very ambitious project.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
Disclosures
Bristol Myers Squibb: Honoraria, Membership on an entity’s Board of Directors or advisory committees; Pfizer: Honoraria, Membership on an entity’s Board of Directors or advisory committees; Janssen: Honoraria, Membership on an entity’s Board of Directors or advisory committees; Menarini Stemline: Honoraria, Membership on an entity’s Board of Directors or advisory committees; Amgen: Honoraria, Membership on an entity’s Board of Directors or advisory committees; Sanofi: Honoraria, Membership on an entity’s Board of Directors or advisory committees; Oncopeptides: Honoraria, Membership on an entity’s Board of Directors or advisory committees.
